Labcorp Earnings: Strong Results Likely to Spill into Fourth Quarter
Labcorp posted third-quarter performance that included revenue and adjusted earnings per share growth of 7% and 15%, respectively. Shares traded up 9% on the news.
Labcorp Holdings Inc LH
Bulls Say, Bears Say
Bulls
There is new bipartisan legislation proposed, the Results Act, which would create a less onerous and more representative method to collect the private-payer reimbursement data to help set Medicare payment rates.
Bears
CMS has indicated that significant numbers of hospital-based labs did not comply with Medicare's payment reporting requirements for PAMA, which could increase reimbursement pressure after 2026.
News
-
Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
-
Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
-
Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential
-
Labcorp Declares Quarterly Dividend
-
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
-
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
-
Labcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health Test
-
Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026
Trading Information
- Previous Close Price
- $360.25
- Day Range
- $351.85–363.50
- 52-Week Range
- $244.61–370.47
- Bid/Ask
- $361.04 / $361.55
- Shares Outstanding
- 81.20M
- Market Cap
- $29.27B
- Volume/Avg
- 419,568 / 733,754
Key Statistics
- Price/Earnings (Normalized)
- 20.60
- Price/Sales
- 2.03
- Dividend Yield (Trailing)
- 0.80%
- Dividend Yield (Forward)
- 0.80%
- Dividend Payment Schedule
- Mar, Jun, Sep, Dec
- Total Yield
- 3.11%
Company Profile
Labcorp is one of the nation’s two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Mid Core
- Total Number of Employees
- 71,000
- Website
- https://www.labcorp.com
Competitors
Valuation
|
Metric
|
LH
|
DGX
|
SHL
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.60 | 22.15 | 14.69 |
Price/Book Value | 3.31 | 3.55 | 1.13 |
Price/Sales | 2.03 | 2.33 | 0.87 |
Price/Cash Flow | 12.98 | 13.72 | 6.71 |
Price/Earnings
LH
DGX
SHL
Financial Strength
|
Metric
|
LH
|
DGX
|
SHL
|
|---|---|---|---|
Quick Ratio | 1.25 | 1.37 | 0.84 |
Current Ratio | 1.80 | 1.70 | 0.99 |
Interest Coverage | 6.43 | 6.53 | 4.98 |
Quick Ratio
LH
DGX
SHL
Profitability
|
Metric
|
LH
|
DGX
|
SHL
|
|---|---|---|---|
Return on Assets (Normalized) | 6.57% | 7.46% | 3.74% |
Return on Equity (Normalized) | 14.08% | 16.81% | 7.39% |
Return on Invested Capital (Normalized) | 9.11% | 10.20% | 5.35% |
Return on Assets
LH
DGX
SHL
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|^&&cvWX$ | LOCK|Nd& | $260B | |||
| Danaher Corp
DHR
| LOCK|&WB^Z^$B | LOCK|QC | $165B | |||
| Agilent Technologies Inc
A
| LOCK|%@qy$^$# | LOCK|!D | $51B | |||
| Waters Corp
WAT
| LOCK|CRG@^G | LOCK|#%Q | $47B | |||
| IQVIA Holdings Inc
IQV
| LOCK|ByjM<#K | LOCK|l#<<& | $46B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|Qx?nQn<Y | LOCK|%<W | $44B | |||
| Illumina Inc
ILMN
| LOCK|G#&^SF | LOCK|$X$!T | $44B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|&r>>mp?< | LOCK|K@J@K | $34B | |||
| Quest Diagnostics Inc
DGX
| LOCK|@%&<h% | LOCK|rRx& | $27B |
United States